DVA vs HALO: fair value comparison
DaVita Inc. and Halozyme Therapeutics, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HALO currently sits closer to the top of our discount ranking. HALO carries the stronger quality grade.
| DVA | HALO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $181.55 | $107.72 |
| 12-month range | $111.19–$240.09 | $63.96–$107.72 |
| Sector rank | #40 of 113 Healthcare | #36 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | Low | High |
| Margin trend | Contracting | Contracting |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: DVA fair value analysis · HALO fair value analysis